Screening for pulmonary arterial hypertension in patients with systemic rheumatic diseases

References

• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9
   Google Scholar
• Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–50
   Google Scholar
• Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996;22:825–40
   PubMedGoogle Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [The Primary Pulmonary Hypertension Study Group]. New Engl J Med 1996;334:296–302
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425–34
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New Engl J Med 2000;342:1866–70
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496–502
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–4
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346: 896–903
   PubMed Web of Science ®Google Scholar
• Cozzi F, Montisci R, Marotta H, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006;36(Suppl 3):49–53
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Farahani KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713–7
   PubMed Web of Science ®Google Scholar
• Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338–42
   Google Scholar
• Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:335–49
   PubMed Web of Science ®Google Scholar
• Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65–74
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92
   PubMed Web of Science ®Google Scholar
• Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657–62
   PubMed Web of Science ®Google Scholar
• Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995;8:1445–9
   PubMed Web of Science ®Google Scholar
• Hachulla E, Gressin V, Guillevin L, et al. Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). Rev Med Interne 2004;25:340–7
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919–23
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7
   PubMed Web of Science ®Google Scholar
• Coghlan JG, Handler C. Connective tissue associated pulmonary arterial hypertension. Lupus 2006;15:138–42
   PubMed Web of Science ®Google Scholar
• Dawson JK, Goodson NG, Graham DR, Lynch MP. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000;39:1320–5
   PubMed Web of Science ®Google Scholar
• Venables PJ. Mixed connective tissue disease. Lupus 2006;15:132–7
   PubMed Web of Science ®Google Scholar
• Winslow TM, Ossipov MA, Fazio GP. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995;129:510–5
   Google Scholar
• Raeside DA, Chalmers G, Clelland J, et al. Pulmonary artery pressure variation in patients with connective tissue disease: 24 hour ambulatory pulmonary artery pressure monitoring. Thorax 1998;53:857–62
   PubMed Web of Science ®Google Scholar